There won’t be any generic versions of Depomed Inc.'s extended-release painkiller Nucynta ER (tapentadol hydrochloride) on pharmacy shelves until 2025 at the earliest (Grünenthal GmbH v. Actavis Elizabeth LLC, D.N.J., 2:13-cv-04507, final judgment and injunction 4/11/17).
Actavis Elizabeth LLC, Alkem Laboratories LLC and Roxane Laboratories Inc. are blocked from launching their generic versions of Nucynta ER until at least late 2025, after a federal judge in New Jersey April 12 entered a final judgment and injunction in a patent case.
The delay in generic competition to Nucynta ER is welcome relief for Depomed Inc. because the Nucynta products ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.